DNMT3A and acute kidney injury: In a meta-analysis of both cohorts, non-DNMT3A-CHIP and large CHIP were associated with a 2.36-fold (95% CI = 1.41–3.93) and 2.40-fold (95% CI = 1.17–4.93) higher odds of nonresolving AKI, respectively (Fig. 2b), whereas DNMT3A-CHIP was not associated with AKI recovery patterns (HR = 0.69, 95% CI = 0.38–1.28).